Studie - Emergency Contraception - France

In 2009, sales of emergency contraception increased by 9% in current value terms, to reach EUR10mn. Demand for emergency contraception remained high, but the 2009 growth rate was lower than 2008. The extensive communication campaign undertaken by the French government and different organisations such as INPES (National Institute for Health Prevention and Education) increased public awareness of STDs (sexually transmitted diseases) and Aids, and as a result the growth rate of emergency...

Euromonitor International's Emergency Contraception Products in France report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2005-2009, allowing you to identify the sectors driving growth. Forecasts to 2014 illustrate how the market is set to change.

Product coverage:

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
* Get a detailed picture of the Consumer Health industry;
* Pinpoint growth sectors and identify factors driving change;
* Understand the competitive environment, the market’s major players and leading brands;
* Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 30 years experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town and Santiago and a network of over 600 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Emergency Contraception in France

Euromonitor International

April 2010

List of Contents and Tables

Executive Summary

Consumer Health Lacks Dynamism

Launch of OTC Obesity Causes Controversy in Consumer Health

Consumer Health Characterised by Fragmented Competitive Environment

Chemists/pharmacies Continue To Dominate Retail Channels

Lack of Growth Will Cause Stagnation

Key Trends and Developments

Self-service: Old Habits Die Hard As Consumers Prefer Advice From Chemists/pharmacists

Consumer Health Battles Against 'alicaments', Highly Functional Foods

Stressful, Busy Lifestyles Influence Natural Choices

Fat Fighting - OTC Obesity Category Launched With New Product Alli

Consumer Health Is Fragmented But Targeted

Market Indicators

Table 1 Consumer Expenditure on Health Goods and Medical Services 2004-2009

Table 2 Life Expectancy at Birth 2004-2009

Market Data

Table 3 Sales of Consumer Health by Sector: Value 2004-2009

Table 4 Sales of Consumer Health by Sector: % Value Growth 2004-2009

Table 5 Consumer Health Company Shares by Value 2005-2009

Table 6 Consumer Health Brand Shares by Value 2006-2009

Table 7 Penetration of Private Label by Sector 2004-2009

Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2004-2009

Table 9 Sales of Consumer Health by Sector and Distribution Format: % Analysis 2009

Table 10 Forecast Sales of Consumer Health by Sector: Value 2009-2014

Table 11 Forecast Sales of Consumer Health by Sector: % Value Growth 2009-2014

Appendix

OTC Registration and Classification

Advertising

Packaging and Labelling

Distribution

Vitamins and Dietary Supplements Registration and Classification

EU Legislation

Self-medication/self-care and Preventive Medicine

Generics

Switches

Summary 1 OTC Healthcare Switches 2007-2009

Definitions

Sector and Subsector Definitions

Summary 2 Research Sources

Arkopharma Sa, Laboratoires Pharmaceutiques

Strategic Direction

Key Facts

Summary 3 Laboratoires Pharmaceutiques Arkopharma SA: Key Facts

Summary 4 Laboratoires Pharmaceutiques Arkopharma SA: Operational Indicators

Company Background

Competitive Positioning

Summary 5 Laboratoires Pharmaceutiques Arkopharma SA: Competitive Position 2009

Beaufour-ipsen SA

Strategic Direction

Key Facts

Summary 6 Beaufour-Ipsen SA: Key Facts

Summary 7 Beaufour-Ipsen SA: Operational Indicators

Company Background

Production

Summary 8 Beaufour-Ipsen SA: Production Statistics

Competitive Positioning

Summary 9 Beaufour-Ipsen SA: Competitive Position 2009

Cooper SA

Strategic Direction

Key Facts

Summary 10 Cooper SA: Key Facts

Summary 11 Cooper SA: Operational Indicators

Company Background

Production

Summary 12 Cooper SA: Production Statistics

Competitive Positioning

Summary 13 Cooper SA: Competitive Position 2009

GlaxoSmithKline Santé Grand Public Sas

Strategic Direction

Key Facts

Summary 14 GlaxoSmithKline Santé Grand Public SAS: Key Facts

Summary 15 GlaxoSmithKline Santé Grand Public SAS: Operational Indicators

Company Background

Production

Summary 16 GlaxoSmithKline France: Production Statistics

Competitive Positioning

Summary 17 GlaxoSmithKline Santé Grand Public SAS: Competitive Position 2009

Juva Santé, Groupe

Strategic Direction

Key Facts

Summary 18 Laboratoires Juva Santé: Key Facts

Company Background

Production

Summary 20 Laboratoires Juva Santé: Production Statistics

Competitive Positioning

Summary 21 Laboratoires Juva Santé: Competitive Position 2009

Laboratoires Mcneil

Strategic Direction

Key Facts

Summary 22 Laboratoires McNeil: Key Facts

Summary 23 Laboratoires McNeil: Operational Indicators

Company Background

Competitive Positioning

Summary 24 Laboratoires McNeil: Competitive Position 2009

Pierre Fabre Sa, Laboratoires

Strategic Direction

Key Facts

Summary 25 Laboratoires Pierre Fabre SA: Key Facts

Summary 26 Laboratoires Pierre Fabre SA: Operational Indicators

Company Background

Production

Summary 27 Laboratoires Pierre Fabre SA: Production Statistics

Competitive Positioning

Summary 28 Laboratoires Pierre Fabre SA: Competitive Position 2009

Théraplix SA

Strategic Direction

Key Facts

Summary 29 Théraplix SA: Key Facts

Company Background

Competitive Positioning

Summary 30 Théraplix SA: Competitive Position 2009

Upsa, Laboratoires

Strategic Direction

Key Facts

Summary 31 Laboratoires UPSA: Key Facts

Summary 32 Laboratoires UPSA: Operational Indicators

Company Background

Production

Summary 33 Laboratoires UPSA: Production Statistics

Competitive Positioning

Summary 34 Laboratoires UPSA: Competitive Position 2009

Urgo, Laboratoires

Strategic Direction

Key Facts

Summary 35 Laboratoires Urgo: Key Facts

Summary 36 Laboratoires Urgo: Operational Indicators

Company Background

Production

Competitive Positioning

Summary 37 Laboratoires Urgo: Competitive Position 2009

Trends

Category Data

Table 12 Sales of Emergency Contraception: Value 2004-2009

Table 13 Sales of Emergency Contraception: % Value Growth 2004-2009

Table 14 Emergency Contraception Company Shares by Value 2005-2009

Table 15 Emergency Contraception Brand Shares by Value 2006-2009

Table 16 Forecast Sales of Emergency Contraception: Value 2009-2014

Table 17 Forecast Sales of Emergency Contraception: % Value Growth 2009-2014

• Women’s Health Therapeutics, Analysis and Market Forecasts to 2016 - High Unmet Need will Drive the Uptake of Novel Drugs in the Menopause and Osteoporosis Markets
• Italy Pharmaceutical Market Overview Generic penetration set to rise
• Dysmenorrhea - Drug Pipeline Analysis and Market Forecasts to 2016
• Emergency Contraception - Bulgaria
• Emergency Contraception - Iran
• Emergency Contraception - Ukraine
• Polycystic Ovarian Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016
• Abnormal Uterine Bleeding Therapy Area Pipeline Report
• Dysmenorrhea Therapy Area Pipeline Report
• Endometriosis Therapy Area Pipeline Report
• Female Sexual Dysfunction Therapy Area Pipeline Report
• Infertility Therapy Area Pipeline Report
• Menopausal Symptoms Therapy Area Pipeline Report
• Vaginal Infections Therapy Area Pipeline Report
• Emergency Contraception - Spain
• Emergency Contraception - Denmark
• Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues
• Pipeline Insight: Endometriosis - New therapies near market while more innovative targets still needed
• Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
• Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types